WHO ICTRP trial
A trial investigating the use of Veregen (EPIgallocatechin-3-gallate) in the…
ISRCTN98495886 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN98495886 |
|---|---|
| Public title | A trial investigating the use of Veregen (EPIgallocatechin-3-gallate) in the treatment of Vulval Intraepithelial Neoplasia |
| Scientific title | Phase II clinical trial investigating the use of EPIgallocatechin-3-gallate (Veregen) in the treatment of Vulval Intraepithelial Neoplasia |
| Primary sponsor | University of Birmingham (UK) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | United Kingdom;England |
| Conditions | Topic: National Cancer Research Network; Subtopic: Gynaecological Cancer; Disease: Vulva Cancer Vulvar intraepithelial neoplasia |
| Interventions | 1. Experimental arm, Veregen 10% 2. Placebo Study Entry: Single Randomisation only |
| Registration date | Dec 17, 2013 |
| Target size | 56 |
| Secondary IDs | 2013-003107-19;15759 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: